MP16-20 INTRAVESICAL BCG TREATMENT IS INVERSELY ASSOCIATED WITH THE RISK OF DEVELOPING ALZHEIMER'S DISEASE OR OTHER DEMENTIA AMONG NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS

Abstract

You have accessJournal of UrologyBladder Cancer: Non-invasive II (MP16)1 Sep 2021MP16-20 INTRAVESICAL BCG TREATMENT IS INVERSELY ASSOCIATED WITH THE RISK OF DEVELOPING ALZHEIMER'S DISEASE OR OTHER DEMENTIA AMONG NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS Joseph Kim, Denzel Zhu, Emily Barry, Evan Kovac, Ahmed Aboumohamed, Ilir Agalliu, and Alex Sankin Joseph KimJoseph Kim More articles by this author , Denzel ZhuDenzel Zhu More articles by this author , Emily BarryEmily Barry More articles by this author , Evan KovacEvan Kovac More articles by this author , Ahmed AboumohamedAhmed Aboumohamed More articles by this author , Ilir AgalliuIlir Agalliu More articles by this author , and Alex SankinAlex Sankin More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002001.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The immune system plays an important role in the pathogenesis of Alzheimer’s disease (AD). Intravesical BCG therapy for non-muscle invasive bladder cancer (NMIBC) has been shown to cause a lasting systemic immune response. In this study, we investigated the association between BCG therapy and subsequent risk of AD and other dementia among a racially diverse cohort of NMIBC patients. METHODS: Using retrospective chart review, we collected data regarding demographics, comorbidities, cancer diagnosis, BCG treatment and subsequent diagnosis of AD or other dementia in a racially diverse cohort of NMIBC patients receiving treatment between 1984 and 2020 in the Montefiore Health System. RESULTS: In our cohort of 1,290 NMIBC patients, patients who received BCG had a 60% lowered actuarial incidence of AD or other dementia (HR=0.41; 95% CI 0.21-0.80) in comparison to those who did not receive BCG, after adjusting for age, gender, race/ethnicity and major comorbidities including heart disease, cerebrovascular disease and diabetes. When we stratified the patients who received BCG by those who only received induction rounds of BCG and those who received both induction and additional maintenance rounds of BCG, patients who received both induction and maintenance rounds of BCG had a further lowered incidence of AD or other dementia (HR=0.23; 95% CI 0.06-0.96) compared to patients who did not receive BCG. CONCLUSIONS: To our knowledge, our study is one of the first to suggest that BCG treatment is associated with a reduced risk of developing AD or other dementia in a multiethnic population with NMIBC, independent of significant comorbidities. Larger cohort studies are needed to corroborate our findings. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e306-e307 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joseph Kim More articles by this author Denzel Zhu More articles by this author Emily Barry More articles by this author Evan Kovac More articles by this author Ahmed Aboumohamed More articles by this author Ilir Agalliu More articles by this author Alex Sankin More articles by this author Expand All Advertisement Loading ...